gribio.com (GRI) - Company Total Revenue
GRI Bio, Inc. (GRI) is highly regarded among immunologists for its innovations in targeted inflammation treatment. The company's current implementation level demonstrates demand dynamics, where 0.00 captures the magnitude of this parameter. The brand's developments are based on NKT-cell modulation to combat organ fibrosis. The firm's operations rely on ESG principles, strict bioethical control, and the minimization of laboratory waste.
Analytical breakdowns for GRI Bio (GRI)
- current price and projected stock value:
- market capitalization indicators:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital Coefficient GRI Bio, Inc.|GRI - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital GRI Bio Inc|GRI - Company Aggregate Debts|Debt to Book Capitalization Ratio GRI Bio, Inc.|GRI - Company Long-Term Debts|Short-Term Debt Volume GRI Bio|Immediate Liquidity gribio.com
- earnings and multiples data:
GRI - Net Income|Expected Net Income GRI Bio, Inc.|GRI - P/E Multiple|Market Cap to Projected Earnings gribio.com|GRI - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation GRI Bio, Inc.|GRI - Operating profit EBITDA|Net earnings per share for the last 12 months GRI Bio|GRI - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months gribio.com|GRI - Earnings growth in current year|Net earnings per one share growth forecast for next year GRI Bio, Inc.
- sales volume and revenue indicators:
Summary company analysis:GRI Bio Corporation
Searching for fundamentally resilient assets requires an analysis of actual cash inflows from product sales, which, in this metric, transform operating cycles into a continuous stream of liquidity. For GRI Bio, Inc. (GRI), the company's sales performance confirms the effectiveness of booking production quotas at bio-factories, guaranteeing a stable volume of inflows even amidst demand volatility for innovative immunoregulators.
Key competitors
Company Sales Volume ARGX (argenx BVBA)|Revenue and Sales Volume BNTX|ABVX - Company Total Revenue|Revenue and Sales Volume ADMA (ADMA Biologics, Inc.)|Company Total Sales Volume Protagonist Therapeutics, Inc.|IMVT - Company Revenue|Company Sales Revenue KNSA (Kiniksa Corp)|GRFS: Revenue and Sales Volume|ADPT - Company Gross Revenue|Company Sales CLDX|AUPH: Company Sales Revenue|Revenue and Sales Volume BCRX|Company Revenue VERA (Vera Corp)|Revenue and Sales Volume DNTH (Dianthus Therapeutics)|Company Gross Revenue pharvaris.com (PHVS)|ABCL - Company Revenue|Company Total Revenue Tourmaline Bio Inc|PGEN (Intrexon) - Company Sales|Pharming Corp - Company Sales Revenue|NKTR (Nektar Therapeutics) - Revenue and Sales Volume|upstreambio.com (UPB) - Company Gross Revenue|Company Revenue Zenas Biopharma (ZBIO)|Immunome Inc - Company Sales Volume|Revenue and Sales Volume GOSS (Gossamer Corp)|KALV - Company Sales|SEPN: Company Sales|Company Gross Revenue pieris.com PVLA|SVRA: Revenue and Sales Volume|Company Total Sales Volume Rigel Pharma RIGL|Company Revenue AnaptysBio Corp|ATXS: Company Sales Revenue|Revenue and Sales Volume ENGN|Company Gross Revenue rapt.com|Company Revenue Aerovate Therapeutics JBIO|ACRS (Aclaris Therapeutics Inc.) - Company Annual Revenue|Kyverna - Revenue and Sales Volume|Company Sales Revenue TLSA (Tiziana Life Sciences, Ltd.)|CABA: Revenue and Sales Volume|ventyxbio.com (VTYX) - Revenue and Sales Volume|Company Revenue Theratechnologies|AVTX: Company Sales Revenue|Company Revenue Eledon (ELDN)|Company Sales Agenus, Inc AGEN|Revenue and Sales Volume CLYM (Climb Bio Inc)|Revenue and Sales Volume zurabio.com ZURA|ATYR: Company Sales|Company Sales Revenue ADAG (Adagene)|IMA: Revenue and Sales Volume|STTK - Company Gross Revenue|Company Revenue Equillium Inc|Company Sales Connect Pharma (CNTB)|Company Revenue Immunic, Inc. (IMUX)|Company Sales atarabio.com ATRA|InflaRx - Company Sales|Revenue and Sales Volume X4 Pharmaceuticals, Inc XFOR|ACET - Company Revenue|CELU (Celularity Inc.) - Company Sales Volume|INMB: Revenue and Sales Volume|Company Total Revenue Barinthus Biotherapeutics PLC (BRNS)|KZR (Kezar Life Sciences, Inc) - Revenue and Sales Volume|SABS - Company Total Sales Volume|Company Revenue Akari Therapeutics (AKTX)|ENLV (enlivex.com) - Company Sales Revenue|Revenue and Sales Volume QTTB (Q32 Bio)|Company Gross Revenue GeoVax Labs (GOVX)|EDSA: Company Sales|Company Sales Revenue IBIO (iBio Corporation)|CARM: Revenue and Sales Volume|XTLB (xtlbio.com) - Company Revenue|BOLT (Bolt Biotherapeutics Inc.) - Revenue and Sales Volume|HCW Biologics Inc (HCWB) - Company Gross Revenue|Company Revenue Aptevo Therapeutics (APVO)|AIM - Company Total Revenue|Aditxt, Inc. - Company Sales|Company Sales Revenue XRTX|Vyome Holdings - Revenue and Sales Volume|Company Gross Revenue Revelation Biosciences Inc REVB|Indaptus (INDP) - Company Revenue|Company Sales Volume SCNI|CALI (CalciMedica Inc) - Revenue and Sales Volume|Company Sales Affimed Therapeutics (AFMD)|Company Sales ALLK (Allakos Inc.)|Company Gross Revenue hookipapharma.com|Revenue and Sales Volume IGMS (IGM Biosciences)|Company Total Sales Volume iTeos Pharma|OCEA - Company Revenue|Company Sales Revenue TCBP (tcbiopharm.com)|THRD: Revenue and Sales Volume
